text: <unk>  is a multikinase inhibitor that is FDA approved for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC)..   Common adverse reactions include diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.
option_0: Cabozantinib
option_1: Encorafenib
option_2: Enasidenib
option_3: Baricitinib
option_4: Regorafenib
option_5: Ivosidenib
option_6: Gilteritinib
option_7: Brigatinib